CSPC Pharmaceutical Group Limited (CSPC) disclosed that the designated trustee for its 2026 Restricted Share Award Scheme purchased 4.40 million shares on-market on 26 June 2026.

The shares, acquired at an average price of HK$6.68, represent approximately 0.04% of CSPC’s issued share capital and involved a total consideration of about HK$29.41 million, excluding transaction costs. Following the transaction, the trustee now holds 46.18 million CSPC shares, equivalent to roughly 0.40% of the company’s outstanding shares.

Separately, BOCI-Prudential Trustee Limited—trustee of the 2018 Share Award Scheme—continues to hold 117.00 million shares under that program.

The board stated it will review and determine future share awards and any additional on-market purchases under both the 2018 and 2026 schemes at its discretion.

The announcement was issued in Hong Kong on 26 June 2026 and signed by Chairman Cai Dong Chen on behalf of the board.